Tapentadol Extended Release
暂无分享,去创建一个
[1] Anthony K. P. Jones,et al. Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol , 2012, Pain practice : the official journal of World Institute of Pain.
[2] A. Sutton,et al. Effect of Tapentadol Extended Release on Productivity: Results From an Analysis Combining Evidence From Multiple Sources , 2012, The Clinical journal of pain.
[3] H. Liedgens,et al. PSY31 Cost-Effectiveness of Tapentadol Prolonged-Release (Pr) Compared to Oxycodone Controlled Release (Cr) in Patients with Chronic Severe Non-Cancer Pain in Ireland , 2011 .
[4] J. Kleijnen,et al. Systematic review of tapentadol in chronic severe pain , 2011, Current medical research and opinion.
[5] J. Goldberg,et al. F644 AN ANALYSIS OF CHANGES IN VITAL SIGNS AND ELECTROCARDIOGRAM MEASUREMENTS WITH TAPENTADOL PROLONGED RELEASE (PR) TREATMENT , 2011 .
[6] C. Hartrick,et al. Tapentadol in Pain Management , 2011, CNS drugs.
[7] J. Vry,et al. Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia , 2011, Journal of Pharmacology and Experimental Therapeutics.
[8] D. Biondi,et al. A post hoc pooled data analysis to evaluate the gastrointestinal tolerability profile of tapentadol extended release (ER) versus oxycodone controlled release (CR) in patients ≥75 years of age , 2011 .
[9] D. Biondi,et al. A post hoc pooled data analysis to evaluate blood pressure (BP) and heart rate (HR) measurements in patients with a current or prior history of hypertension who received tapentadol ER, oxycodone CR, or placebo in chronic pain studies , 2011 .
[10] S. Schwartz,et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial , 2010, Current medical research and opinion.
[11] H. Liedgens,et al. PSY34 COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH CHRONIC MODERATE TO SEVERE NON-CANCER PAIN IN SWEDEN , 2010 .
[12] B. Kuperwasser,et al. 337 HEALTH STATUS OF PATIENTS WHO RECEIVED TAPENTADOL PROLONGED RELEASE DURING AN OPEN-LABEL EXTENSION STUDY , 2010 .
[13] C. Rauschkolb,et al. A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. , 2010, International journal of clinical pharmacology and therapeutics.
[14] J. Frampton. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. , 2010, Drugs.
[15] C. Rauschkolb,et al. Long‐term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain , 2010, Pain practice : the official journal of World Institute of Pain.
[16] J. Vry,et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain , 2010, European journal of pain.
[17] H. Kress. Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally‐acting analgesics on the horizon? , 2010, European journal of pain.
[18] C. Rauschkolb,et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study , 2010, Expert opinion on pharmacotherapy.
[19] A. Okamoto,et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain , 2010, Advances in therapy.
[20] C. Rauschkolb,et al. 292 TAPENTADOL PROLONGED RELEASE (PR) FOR PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN): EFFICACY AND SAFETY BY PRIOR OPIOID EXPERIENCE AND DOSE CATEGORY , 2010 .
[21] D. Biondi,et al. Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: influence of prior opioid experience on study discontinuations due to constipation, nausea, or vomiting , 2010 .
[22] D. Biondi,et al. Tapentadol extended release (ER) versus oxycodone controlled release (CR) for management of chronic low back or osteoarthritis pain: analyses of study discontinuations due to constipation, nausea, or vomiting , 2010 .
[23] J. Smit,et al. Effects of Acetaminophen, Naproxen, and Acetylsalicylic Acid on Tapentadol Pharmacokinetics: Results of Two Randomized, Open‐Label, Crossover, Drug‐Drug Interaction Studies , 2010, Pharmacotherapy.
[24] J. Haeussler,et al. 707 ANALYSIS OF EFFICACY AND SAFETY OF TAPENTADOL EXTENDED RELEASE (ER) FOR CHRONIC LOW BACK PAIN BASED ON PRIOR OPIOID EXPERIENCE , 2009 .
[25] G. Pasternak,et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. , 2009, The journal of pain : official journal of the American Pain Society.
[26] R. Chou,et al. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. , 2009, The journal of pain : official journal of the American Pain Society.
[27] B. Dasgupta,et al. Sarcoid sacroiliitis: successful treatment with infliximab , 2009, Annals of the rheumatic diseases.
[28] K. Schiene,et al. (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties , 2007, Journal of Pharmacology and Experimental Therapeutics.
[29] Iris Pigeot,et al. Establishing Efficacy of a New Experimental Treatment in the ‘Gold Standard’ Design , 2005, Biometrical journal. Biometrische Zeitschrift.
[30] J. Foss,et al. Are Peripheral Opioid Antagonists the Solution to Opioid Side Effects? , 2004, Anesthesia and analgesia.
[31] B. Nicholson. Responsible Prescribing of Opioids for the Management of Chronic Pain , 2012, Drugs.
[32] C. Rauschkolb,et al. Dose conversion between tapentadol immediate and extended release for low back pain. , 2010, Pain physician.
[33] M. Afilalo,et al. Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee , 2010, Clinical drug investigation.
[34] C. Rauschkolb,et al. Health-related outcomes associated with tapentadol extended release (ER) treatment for the management of painful diabetic peripheral neuropathy (DPN): results of a randomized-withdrawal phase 3 trial , 2009 .
[35] A. Okamoto,et al. Health status (EuroQol-5 Dimension [EQ-5D]) in patients with painful diabetic peripheral neuropathy (DPN) treated with tapentadol extended release (ER): results of a randomized-withdrawal phase 3 study , 2009 .